dc.contributor.author | Mirza, NB | |
dc.contributor.author | Wamola, IA | |
dc.contributor.author | Estambale, Benson | |
dc.contributor.author | Mbithi, E | |
dc.contributor.author | Poillet, M. | |
dc.date.accessioned | 2013-06-10T13:00:56Z | |
dc.date.available | 2013-06-10T13:00:56Z | |
dc.date.issued | 1995 | |
dc.identifier.citation | Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya. Mirza NB, Wamola IA, Estambale BA, Mbithi E, Poillet M. East Afr Med J. 1995 Mar;72(3):162-4. | en |
dc.identifier.uri | http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/7796767 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/30871 | |
dc.description.abstract | Safety, tolerance and immunogenicity of the purified Vi polysaccharide vaccine (Typhim Vi) against typhoid fever was evaluated in primary school children aged 5-15 years. A total of 435 children were vaccinated, each with a single intramuscular injection in the left deltoid muscle. One hundred and ten children were randomly selected for blood samples on day 0 (pre vaccination) and day 30 (post vaccination). Vi antibodies studied by Radio immuno assay (RIA) on 97(88%) paired sera showed a seroconversion rate of 76.2% and seroprotection rate after vaccination was 74.2%, while 6.2% of children already had protective immunity before vaccination. The vaccine was well tolerated. Most commonly reported reactions were mild pain at site of injection (83%), and a few complained of mild swelling (4.6%), induration (1.1%), itching (1.1%) and headaches (1.4%). All reactions were of mild severity and disappeared within 24 to 48 hours. | en |
dc.language.iso | en | en |
dc.title | Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya. | en |
dc.type | Article | en |
local.publisher | Medical Microbiology, University of Nairobi | en |